Search
Benfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnIt was patented and manufactured by a French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.
Isoflavone
go.drugbank.com/drugs/DB12007ApprovedInvestigationalWithdrawnIsoflavone is a soy phytoestrogen and a biologically active component of several agriculturally important legumes such as soy, peanut, green peas, chick peas and alfalfa . Soybean is an exceptionally rich source of dietary isoflavones, w...
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigational[L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment
OPC-14523
go.drugbank.com/drugs/DB05422ExperimentalOPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.
Brompheniramine
go.drugbank.com/drugs/DB00835ApprovedHistamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
Mixtures: Up and Up Childrens Cold and CoughIpilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]
Adenosine phosphate
go.drugbank.com/drugs/DB00131ApprovedInvestigationalNutraceuticalWithdrawnAdenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]
Barnidipine
go.drugbank.com/drugs/DB09227InvestigationalIn two European multicentre randomized, double-blind trials, barnidipine was shown to possess equivalent antihypertensive efficacy to amlodipine and nitrendipine, but produced fewer class-specific side-effects … multicentre, placebo-controlled, double-blind study in patients with mild to moderate hypertension, the antihypertensive response from barnidipine treatment was maintained after a 1-year and 2-year follow-up
Pemivibart
go.drugbank.com/drugs/DB18720InvestigationalPemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COV...
Meningococcal polysaccharide vaccine group Y
go.drugbank.com/drugs/DB13888ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.